Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives

Attralus, backed by venBio Partners, recruits new leadership team to support advancement of its pipeline to bring transformational pan-amyloid removal therapies to the systemic amyloidosis field

May 10, 2021 07:00 AM Eastern Daylight Time

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Attralus Therapeutics today announced the appointment of Mark Timney as the company’s Chief Executive Officer and a member of its Board of Directors. Timney brings to Attralus more than 30 years of leadership experience at publicly traded and global biopharmaceutical companies, including his most recent role as CEO of The Medicines Company (NASDAQ: MDCO) until its sale for $9.7 billion to Novartis AG (NYSE: NVS) which was completed in 2020. Timney joins Attralus to accelerate clinical development of its product pipeline and expand the company’s business plan. Spencer Guthrie, the co-founder who led the company during early development, will continue at Attralus as Chief Operating Officer.